

WPS GHA
J5 Contractor Advisory Committee Meeting

Moderator: Dr. Robert Kettler
June 18, 2020
4:00 PM CT

OPERATOR: This is Conference # 6763028.

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the J5 MAC Advisory Committee Meeting.

At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star, then the number one on your telephone. If you require any further assistance, please press star, zero.

I would now like to hand the conference over to your speaker today, Kit Young. Thank you. Please go ahead.

Dr. Kit Young: Thank you very much. I'd like to welcome everybody to virtual sunny St. Louis for the Spring CAC Meeting. My name Kit Young. I'm the Missouri CAC Chair and I'm an anesthesiologist. I would like to welcome everybody to the meeting. And at this point, I will turn it over to Dr. Kettler for introductions and LCD consideration.

Dr. Robert Kettler: Thank you, Dr. Young. And I think what I'll do is we'll go through the LCDs first and, then, take any comments on those and, then, we'll go do the introductions after that.

The first LCD is draft LCD 38682. It's the Fluid Jet System Treatment for Lower Urinary Tract Symptoms, or LUTS, and Benign Prostatic Hypertrophy, or BPH. This LCD establishes coverage requirements for a once-per-lifetime fluid jet system management of lower urinary tract symptoms and BPH.

And what we will do now after the – each LCD has been introduced is we will take any comments. And while the public testimony is an important part of this, we also ask that you submit any comments you have in writing to

policycomments@wpsic.com so that we are sure that we have the comments right.

And I do have one correction that I'd like to suggest for this LCD. On page five in the background section, the second paragraph, I think there is a typo. It talks about (TUP) syndrome, and I think it should be TURP syndrome. And I will send that into policy comments.

With that, then, (Rochelle), could you see if anybody on the line has any comments?

Operator: All right. One moment. As a reminder, to ask a question if you have a comment, you may press star, one on your telephone.

Dr. Robert Kettler: Thank you.

Operator: As of the moment, you don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. Moving on, then, to the next LCD. This is draft LCD 37913, MolDX Breast Cancer Index, or BCI Gene Expression Test. And this LCD establishes limited coverage for BCI gene expression test in select patients. And the purpose of the test is to estimate the recurrence risk and responsiveness to endocrine therapy.

(Rochelle), we can take any comments on the line.

Operator: Ladies and gentlemen, if you have any comments, you may press star, one. We don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. The next LCD is draft LCD 38684, MolDX Prognostic and Predictive Molecular Classifiers for Bladder Cancer. This LCD establishes criteria for coverage of molecular diagnostic tests in bladder cancer.

And (Rochelle), do we have any comments on the line?

Operator: Once again, you may press star, one if you would like to have a comment. We don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. The next LCD is draft LCD 38678. The title is MoIDX Phenotypic Biomarker Detection in Circulating Tumor Cells. And this is, again, a limited-coverage LCD which establishes criteria for coverage of assays that detect circulating HER2-positive cells.

(Rochelle), do we – (Rochelle), do we have any comments?

Operator: We don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. Next is draft LCD 38680. The title is Liquid Biopsies for Solid Organ Transplantation. This LCD establishes criteria for the coverage of blood samples to assess the rejection of a transplanted allograft.

And do we have any comments on the line?

Operator: You don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. The next LCD is LCD 37663, MoIDX EndoPredict Breast Cancer Gene Expression Test. This LCD establishes limited coverage for – or establishes – this is a limited-coverage LCD which establishes criteria for coverage of this test, which is intended to identify breast cancer patients who are at low risk for a 10-year distant recurrence and so may be considered for foregoing chemotherapy.

Any comments on this LCD?

Operator: Once again, if you have any comment, you have press star, one. We don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. Next, draft LCD L38213. This is Percutaneous Vertebral Augmentation for Osteoporotic for Vertebral Compression Fracture. This LCD establishes coverage criteria for vertebral augmentation procedures in patients who have experienced vertebral compression fractures. This is an LCD that is a product of a multi-MAC collaborative group. It is a revision of an existing LCD based on comment that was received on the previous LCD.

And is there any comment on this LCD, (Rochelle)?

Operator: We don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. And the last LCD is LCD 38686, Implantable Continuous Glucose Monitors. And this LCD supplements an existing national coverage determination for implantable glucose monitors providing additional coverage criteria.

Are there any comments on this LCD?

Operator: Once again, you may press star, one for any comments. We don't have anyone on the queue.

Dr. Robert Kettler: OK. Thank you. That completes the LCD portion of the CAC meeting. So, (Rochelle), those who are observers can leave the meeting now, and we will just stay with our CAC members for now.

Operator: OK. Thank you.

Dr. Robert Kettler: And while we are taking care of that, I'll just start the introductions by introducing myself.

I am Bob Kettler. I am an anesthesiologist, and ...